RNA-mediated Activation of MRNA Cap Methyltransferase Subunit-like

Target Name: RAMACL

NCBI ID: G353267

RAMACL

RNA-mediated Activation of MRNA Cap Methyltransferase Subunit-like

RAMACL (RNA-mediated activation of mRNA cap methyltransferase subunit-like) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The RAMACL gene is located on chromosome 6 and encodes for the mRNA cap methyltransferase subunit- like protein (pseudogene), which is involved in the regulation of gene expression.

The mRNA cap methyltransferase is a complex protein that is responsible for modifying the mRNA cap, which is the region of the mRNA that contains information on the structure and function of the protein. The mRNA cap methyltransferase subunit-like protein helps to add a methyl group to the mRNA cap, which can interact with the protein encoded by the gene.

Studies have shown that the mRNA cap methyltransferase is involved in the regulation of many different genes, including those involved in cell growth, differentiation, and stress responses. It has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the challenges in studying the mRNA cap methyltransferase is its complex structure. The protein is composed of several subunits that are held together by non-covalent bonds. These subunits include the N-terminal alpha-helix, the B-layer, and the C-layer. The C-layer contains the active site for the methyltransferase, which is responsible for adding the methyl group to the mRNA cap.

In addition to its role in gene regulation, RAMACL has also been shown to play a role in the development and progression of cancer. It has been shown to be involved in the regulation of the expression of genes involved in cell growth, migration, and invasion , as well as in the regulation of cell apoptosis.

Furthermore, RAMACL has also been shown to be involved in the regulation of neurodegenerative diseases. It has been implicated in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, due to its role in the regulation of genes involved in neurotransmitter synthesis and release.

In conclusion, RAMACL is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. Its role in the regulation of gene expression and the development and progression of cancer, as well as neurodegenerative diseases, makes it an attractive target for further study. Further research is needed to fully understand the mechanisms of RAMACL's function and its potential as a drug.

Protein Name: RNA Guanine-7 Methyltransferase Activating Subunit Like

The "RAMACL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAMACL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets